Organon & Co (OGN) Stock AnalysisOGNStock AnalysisOrganon & Co

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Organon & Co (OGN) is a good buy right now at $13.76, especially considering its forward P/E of 5.09, which indicates strong earnings potential relative to its price. Additionally, the stock has shown a remarkable year-to-date change of +90.06%, reflecting strong market interest. The main risk is its recent net income fluctuations, including a negative net income of -205 million in Q4 2025, which could affect future performance.